Kessler Topaz Meltzer & Check Encourages RARE Investors to Act on Losses
Investor Alert: Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP, a well-known plaintiff-side law firm, has reached out to investors regarding the recent developments involving Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). If you purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, you may be eligible to take action following a significant securities fraud class action lawsuit that has been filed against the company.
Background of the Lawsuit
The complaint, currently registered in the United States District Court for the Northern District of California, alleges that Ultragenyx misled its investors during the class period by making false or misleading statements. Key points in the lawsuit include:
- - The firm is accused of creating a false impression about their drug, setrusumab, and its efficacy in treating various types of Osteogenesis Imperfecta.
- - Investors were kept in the dark about the misleading nature of the drug's results and the risks associated with the Phase III Orbit study.
- - Reports indicated that the optimistic assertions made by Ultragenyx regarding clinical trials were unfounded, primarily since results were based on earlier studies without proper controls.
On December 29, 2025, Ultragenyx’s stock price plummeted by over 42% following the announcement that their Phase III Orbit and Cosmic trials did not meet the primary endpoints concerning the reduction of annualized clinical fracture rates.
What Affected Investors Should Do
Investors who believe they may have suffered losses are urged to take the following actions:
1. Seek Lead Plaintiff Status: You have until April 6, 2026, to file for lead plaintiff status. This role will allow you to direct the litigation on behalf of other investors.
2. Contact Kessler Topaz Meltzer & Check: You can reach out to their attorney Jonathan Naji for a complimentary case evaluation. There’s no obligation to pursue the matter further, and it may provide a clearer understanding of your legal rights.
3. Decide on Legal Representation: You have the option to hire counsel of your choice or to remain an absent class member, with the ability to still share in any potential recovery.
Why It Matters
The outcome of this lawsuit could potentially lead to significant recoveries for investors who suffered losses due to the alleged misstatements. Kessler Topaz Meltzer & Check has a strong track record in handling securities fraud cases and has secured over $25 billion in recoveries for investors over the years. Their expertise in this field could provide invaluable support for affected investors.
Conclusion
If you purchased Ultragenyx shares within the specified period and face losses, now is the time to act. With the deadline approaching to secure your status as a lead plaintiff, staying informed and proactive is essential. For further information or to initiate a conversation about your case, reach out to Kessler Topaz Meltzer & Check at the contact information provided.
As always, the firm's assessment of your case will be free of charge, ensuring that your financial interests come first.
For additional resources and updates, consider visiting Kessler Topaz’s website.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.